These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 28101917)

  • 41. Malignant and borderline epithelial ovarian tumors in the pediatric and adolescent population.
    Nasioudis D; Alevizakos M; Holcomb K; Witkin SS
    Maturitas; 2017 Feb; 96():45-50. PubMed ID: 28041594
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Borderline ovarian tumors: French guidelines from the CNGOF. Part 1. Epidemiology, biopathology, imaging and biomarkers.
    Huchon C; Bourdel N; Abdel Wahab C; Azaïs H; Bendifallah S; Bolze PA; Brun JL; Canlorbe G; Chauvet P; Chereau E; Courbiere B; De La Motte Rouge T; Devouassoux-Shisheboran M; Eymerit-Morin C; Fauvet R; Gauroy E; Gauthier T; Grynberg M; Koskas M; Larouzee E; Lecointre L; Levêque J; Margueritte F; Mathieu D'argent E; Nyangoh-Timoh K; Ouldamer L; Raad J; Raimond E; Ramanah R; Rolland L; Rousset P; Rousset-Jablonski C; Thomassin-Naggara I; Uzan C; Zilliox M; Daraï E
    J Gynecol Obstet Hum Reprod; 2021 Jan; 50(1):101965. PubMed ID: 33160106
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Low-malignant potential epithelial tumors of the ovary: a clinicopathological study.
    Hassan E; Koumantaki Y; Stefanaki K; Matalliotakis I; Koumantakis E
    Eur J Gynaecol Oncol; 1998; 19(2):170-2. PubMed ID: 9611060
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Imaging in gynecological disease (23): clinical and ultrasound characteristics of ovarian carcinosarcoma.
    Ciccarone F; Biscione A; Moro F; Fischerova D; Savelli L; Munaretto M; Jokubkiene L; Sladkevicius P; Chiappa V; Fruscio R; Franchi D; Epstein E; Timmerman D; Froyman W; Valentin L; Scambia G; Testa AC
    Ultrasound Obstet Gynecol; 2022 Feb; 59(2):241-247. PubMed ID: 34225386
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Imaging in gynecological disease (22): clinical and ultrasound characteristics of ovarian embryonal carcinomas, non-gestational choriocarcinomas and malignant mixed germ cell tumors.
    Moro F; Castellano LM; Franchi D; Epstein E; Fischerova D; Froyman W; Timmerman D; Zannoni GF; Scambia G; Valentin L; Testa AC; Mascilini F
    Ultrasound Obstet Gynecol; 2021 Jun; 57(6):987-994. PubMed ID: 33142349
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The serum CA-125 concentration data assists in evaluating CT imaging information when used to differentiate borderline ovarian tumor from malignant epithelial ovarian tumors.
    Shin JE; Choi HJ; Kim MH; Cho KS
    Korean J Radiol; 2011; 12(4):456-62. PubMed ID: 21852906
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of clinical behavior between mucinous ovarian carcinoma with infiltrative and expansile invasion and high-grade serous ovarian carcinoma: a retrospective analysis.
    Hada T; Miyamoto M; Ishibashi H; Matsuura H; Kakimoto S; Iwahashi H; Tsuda H; Takano M
    Diagn Pathol; 2022 Jan; 17(1):12. PubMed ID: 35057833
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The role of CnTI-SonoVue in the diagnosis of ovarian masses with papillary projections: a preliminary study.
    Testa AC; Timmerman D; Exacoustos C; Fruscella E; Van Holsbeke C; Bokor D; Arduini D; Scambia G; Ferrandina G
    Ultrasound Obstet Gynecol; 2007 May; 29(5):512-6. PubMed ID: 17444549
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Unilocular adnexal cysts with papillary projections but no other solid components: is there a diagnostic method that can classify them reliably as benign or malignant before surgery?
    Valentin L; Ameye L; Savelli L; Fruscio R; Leone FP; Czekierdowski A; Lissoni AA; Fischerova D; Guerriero S; Van Holsbeke C; Van Huffel S; Timmerman D
    Ultrasound Obstet Gynecol; 2013 May; 41(5):570-81. PubMed ID: 22915541
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Risk of specific types of ovarian cancer after borderline ovarian tumors in Denmark: A nationwide study.
    Hannibal CG; Frederiksen K; Vang R; Kurman RJ; Kjaer SK
    Int J Cancer; 2020 Aug; 147(4):990-995. PubMed ID: 31930502
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lymph Node Involvement Pattern and Survival Differences of FIGO IIIC and FIGO IIIA1 Ovarian Cancer Patients After Primary Complete Tumor Debulking Surgery: A 10-Year Retrospective Analysis of the Tumor Bank Ovarian Cancer Network.
    Gasimli K; Braicu EI; Nassir M; Richter R; Babayeva A; Chekerov R; Darb-Esfahani S; Sehouli J; Muallem MZ
    Ann Surg Oncol; 2016 Apr; 23(4):1279-86. PubMed ID: 26832880
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis.
    Dehari R; Kurman RJ; Logani S; Shih IeM
    Am J Surg Pathol; 2007 Jul; 31(7):1007-12. PubMed ID: 17592266
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Testing for
    Sadlecki P; Grzanka D; Grabiec M
    Dis Markers; 2018; 2018():1497879. PubMed ID: 29682098
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Characterization of TP53-wildtype tubo-ovarian high-grade serous carcinomas: rare exceptions to the binary classification of ovarian serous carcinoma.
    Chui MH; Momeni Boroujeni A; Mandelker D; Ladanyi M; Soslow RA
    Mod Pathol; 2021 Feb; 34(2):490-501. PubMed ID: 32801341
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Imaging in gynecological disease (9): clinical and ultrasound characteristics of tubal cancer.
    Ludovisi M; De Blasis I; Virgilio B; Fischerova D; Franchi D; Pascual MA; Savelli L; Epstein E; Van Holsbeke C; Guerriero S; Czekierdowski A; Zannoni G; Scambia G; Jurkovic D; Rossi A; Timmerman D; Valentin L; Testa AC
    Ultrasound Obstet Gynecol; 2014 Mar; 43(3):328-35. PubMed ID: 23893713
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ovarian cancer arising in endometrioid cysts: ultrasound findings.
    Testa AC; Timmerman D; Van Holsbeke C; Zannoni GF; Fransis S; Moerman P; Vellone V; Mascilini F; Licameli A; Ludovisi M; Di Legge A; Scambia G; Ferrandina G
    Ultrasound Obstet Gynecol; 2011 Jul; 38(1):99-106. PubMed ID: 21351179
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis.
    Sherman ME; Mink PJ; Curtis R; Cote TR; Brooks S; Hartge P; Devesa S
    Cancer; 2004 Mar; 100(5):1045-52. PubMed ID: 14983501
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of MTAP immunohistochemistry loss of expression in ovarian serous borderline tumors as a potential marker for prognosis and progression.
    Nilforoushan N; Moatamed NA
    Ann Diagn Pathol; 2020 Oct; 48():151582. PubMed ID: 32866902
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ovarian serous tumors of low malignant potential with nodal low-grade serous carcinoma.
    Djordjevic B; Malpica A
    Am J Surg Pathol; 2012 Jul; 36(7):955-63. PubMed ID: 22613998
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Expression and prognostic significance of epithelial-mesenchymal transition-related markers and phenotype in serous ovarian cancer.
    Song IH; Kim KR; Lim S; Kim SH; Sung CO
    Pathol Res Pract; 2018 Oct; 214(10):1564-1571. PubMed ID: 30082157
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.